Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 4.54
OCUL's Cash-to-Debt is ranked lower than
63% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. OCUL: 4.54 )
Ranked among companies with meaningful Cash-to-Debt only.
OCUL' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.36  Med: 6.29 Max: N/A
Current: 4.54
Equity-to-Asset 0.71
OCUL's Equity-to-Asset is ranked higher than
54% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OCUL: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
OCUL' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.9  Med: 0.76 Max: 0.84
Current: 0.71
-2.9
0.84
Piotroski F-Score: 2
Altman Z-Score: 0.69
Beneish M-Score: -0.12
WACC vs ROIC
12.13%
-4902.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2546.69
OCUL's Operating Margin % is ranked lower than
85% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. OCUL: -2546.69 )
Ranked among companies with meaningful Operating Margin % only.
OCUL' s Operating Margin % Range Over the Past 10 Years
Min: -136710  Med: -2902.81 Max: -2182.69
Current: -2546.69
-136710
-2182.69
Net Margin % -2620.06
OCUL's Net Margin % is ranked lower than
86% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. OCUL: -2620.06 )
Ranked among companies with meaningful Net Margin % only.
OCUL' s Net Margin % Range Over the Past 10 Years
Min: -140930  Med: -3039.94 Max: -2271.31
Current: -2620.06
-140930
-2271.31
ROE % -75.85
OCUL's ROE % is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. OCUL: -75.85 )
Ranked among companies with meaningful ROE % only.
OCUL' s ROE % Range Over the Past 10 Years
Min: -75.85  Med: -58.38 Max: -53.61
Current: -75.85
-75.85
-53.61
ROA % -56.91
OCUL's ROA % is ranked lower than
70% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. OCUL: -56.91 )
Ranked among companies with meaningful ROA % only.
OCUL' s ROA % Range Over the Past 10 Years
Min: -59.94  Med: -55.74 Max: -42.17
Current: -56.91
-59.94
-42.17
ROC (Joel Greenblatt) % -1260.82
OCUL's ROC (Joel Greenblatt) % is ranked lower than
65% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. OCUL: -1260.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OCUL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2049.81  Med: -1559.32 Max: -1260.82
Current: -1260.82
-2049.81
-1260.82
3-Year EBITDA Growth Rate 25.70
OCUL's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. OCUL: 25.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OCUL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.85 Max: 25.7
Current: 25.7
0
25.7
3-Year EPS without NRI Growth Rate 25.50
OCUL's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. OCUL: 25.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OCUL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.75 Max: 25.5
Current: 25.5
0
25.5
GuruFocus has detected 4 Warning Signs with Ocular Therapeutix Inc $OCUL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OCUL's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

OCUL Guru Trades in Q2 2016

Jim Simons 47,300 sh (New)
» More
Q3 2016

OCUL Guru Trades in Q3 2016

Jim Simons Sold Out
» More
Q4 2016

OCUL Guru Trades in Q4 2016

Jim Simons 145,100 sh (New)
» More
Q1 2017

OCUL Guru Trades in Q1 2017

Jim Simons 88,900 sh (-38.73%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:OCUL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ATHX, NAS:MNOV, NAS:ALT, NAS:MACK, NAS:MDGL, NAS:KIN, TSX:VBV, OTCPK:BBLG, NAS:KURA, NAS:GEMP, AMEX:AST, NAS:CNAT, NAS:XBIT, NAS:CASC, NAS:BDSI, NAS:CDXC, NYSE:KDMN, NAS:CBAY, TSX:HSM, NAS:TRVN » details
Traded in other countries:0OT.Germany,
Headquarter Location:USA
Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

Ocular Therapeutix is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.

Top Ranked Articles about Ocular Therapeutix Inc

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL
OCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ocular Therapeutix, Inc. To Contact The Firm
Investor Alert: Kaplan Fox Announces Investigation Of Ocular Therapeutix, Inc.
Safirstein Metcalf LLP Announces that A Class Action Has Been Filed Against Ocular Therapeutix, Inc. – OCUL
EQUITY ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Ocular Therapeutix, Inc.
RM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ocular Therapeutix, Inc. and Certain Officers – OCUL
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm

Ratios

vs
industry
vs
history
PB Ratio 3.02
OCUL's PB Ratio is ranked lower than
52% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. OCUL: 3.02 )
Ranked among companies with meaningful PB Ratio only.
OCUL' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 4.06 Max: 17.67
Current: 3.02
1.54
17.67
PS Ratio 89.60
OCUL's PS Ratio is ranked lower than
88% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. OCUL: 89.60 )
Ranked among companies with meaningful PS Ratio only.
OCUL' s PS Ratio Range Over the Past 10 Years
Min: 60.69  Med: 135.33 Max: 1057.5
Current: 89.6
60.69
1057.5
EV-to-EBIT -2.75
OCUL's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. OCUL: -2.75 )
Ranked among companies with meaningful EV-to-EBIT only.
OCUL' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.3  Med: -4.5 Max: -0.9
Current: -2.75
-31.3
-0.9
EV-to-EBITDA -2.80
OCUL's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. OCUL: -2.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCUL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32  Med: -4.6 Max: -0.9
Current: -2.8
-32
-0.9
Current Ratio 9.62
OCUL's Current Ratio is ranked higher than
78% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. OCUL: 9.62 )
Ranked among companies with meaningful Current Ratio only.
OCUL' s Current Ratio Range Over the Past 10 Years
Min: 5.03  Med: 10 Max: 24.35
Current: 9.62
5.03
24.35
Quick Ratio 9.61
OCUL's Quick Ratio is ranked higher than
79% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. OCUL: 9.61 )
Ranked among companies with meaningful Quick Ratio only.
OCUL' s Quick Ratio Range Over the Past 10 Years
Min: 5.01  Med: 9.98 Max: 24.31
Current: 9.61
5.01
24.31
Days Inventory 97.17
OCUL's Days Inventory is ranked higher than
64% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. OCUL: 97.17 )
Ranked among companies with meaningful Days Inventory only.
OCUL' s Days Inventory Range Over the Past 10 Years
Min: 97.17  Med: 152.75 Max: 266.73
Current: 97.17
97.17
266.73
Days Sales Outstanding 46.78
OCUL's Days Sales Outstanding is ranked higher than
66% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. OCUL: 46.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCUL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.25  Med: 101.96 Max: 1642.5
Current: 46.78
40.25
1642.5
Days Payable 2.00
OCUL's Days Payable is ranked lower than
94% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. OCUL: 2.00 )
Ranked among companies with meaningful Days Payable only.
OCUL' s Days Payable Range Over the Past 10 Years
Min: 2  Med: 3758.83 Max: 30399.29
Current: 2
2
30399.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.70
OCUL's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. OCUL: -19.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCUL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.7  Med: -9.85 Max: 0
Current: -19.7
-19.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.61
OCUL's Price-to-Net-Cash is ranked higher than
64% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. OCUL: 3.61 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OCUL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.9  Med: 4.62 Max: 18.75
Current: 3.61
1.9
18.75
Price-to-Net-Current-Asset-Value 3.43
OCUL's Price-to-Net-Current-Asset-Value is ranked higher than
65% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. OCUL: 3.43 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OCUL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.88  Med: 4.45 Max: 17.94
Current: 3.43
1.88
17.94
Price-to-Tangible-Book 3.02
OCUL's Price-to-Tangible-Book is ranked higher than
56% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. OCUL: 3.02 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OCUL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.74  Med: 4.03 Max: 17.27
Current: 3.02
1.74
17.27
Price-to-Median-PS-Value 0.66
OCUL's Price-to-Median-PS-Value is ranked higher than
54% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. OCUL: 0.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OCUL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 0.95 Max: 6.9
Current: 0.66
0.51
6.9
Earnings Yield (Greenblatt) % -36.36
OCUL's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. OCUL: -36.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OCUL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -107.5  Med: -22.1 Max: -3.2
Current: -36.36
-107.5
-3.2

More Statistics

Revenue (TTM) (Mil) $1.90
EPS (TTM) $ -1.94
Beta1.66
Short Percentage of Float34.33%
52-Week Range $4.04 - 11.91
Shares Outstanding (Mil)29.03

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -2.09 -2.05 -1.33
EPS without NRI ($) -2.09 -2.05 -1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OCUL

Headlines

Articles On GuruFocus.com
Safirstein Metcalf LLP Announces that A Class Action Has Been Filed Against Ocular Therapeutix, Inc. Jul 13 2017 
EQUITY ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Ocul Jul 12 2017 
RM LAW Announces Class Action Lawsuit Against Ocular Therapeutix, Inc. Jul 12 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Ocular Therapeu Jul 12 2017 
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Thera Jul 12 2017 
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocul Jul 12 2017 
IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Ocula Jul 12 2017 
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Jul 11 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ocu Jul 10 2017 
Block & Leviton Announces Class Action Lawsuit Against Ocular Therapeutix, Inc. (OCUL) And Encourage Jul 10 2017 

More From Other Websites
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular... Jul 21 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular... Jul 21 2017
OCUL INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Jul 21 2017
SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular... Jul 20 2017
OCUL SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a... Jul 20 2017
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Ocular Therapeutix, Inc. Jul 19 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ocular Therapeutix, Inc. of a Class... Jul 19 2017
OCULAR THERAPEUTIX ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding... Jul 19 2017
EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix,... Jul 19 2017
Investor Alert: Kaplan Fox Announces Investigation Of Ocular Therapeutix, Inc. Jul 19 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against... Jul 19 2017
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular... Jul 18 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocular Therapeutix, Inc. of a... Jul 18 2017
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular... Jul 17 2017
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal... Jul 17 2017
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of... Jul 17 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against... Jul 14 2017
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal... Jul 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}